Published in Cell on April 17, 1998
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest (2000) 4.54
Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One (2008) 4.37
The stem cell niches in bone. J Clin Invest (2006) 4.11
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev (1999) 3.88
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med (2012) 3.46
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A (2000) 3.37
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest (2003) 3.14
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Osteoclasts: what do they do and how do they do it? Am J Pathol (2007) 2.93
Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol (2000) 2.87
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med (1998) 2.68
Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev (2008) 2.64
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A (2001) 2.56
B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 2.56
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest (2001) 2.49
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Cellular and molecular mechanisms of bone remodeling. J Biol Chem (2010) 2.39
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest (2000) 2.32
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther (2007) 2.30
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol (2012) 2.28
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol (2007) 2.25
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A (2000) 2.20
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Bone destruction in arthritis. Ann Rheum Dis (2002) 2.15
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med (1999) 2.13
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem (2012) 2.08
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Effects of obesity on bone metabolism. J Orthop Surg Res (2011) 2.06
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med (2002) 2.04
Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A (1999) 2.04
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol (2000) 1.99
High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol (2002) 1.95
Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica (2015) 1.94
Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med (2000) 1.93
Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest (2006) 1.92
Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol (2006) 1.92
Paget disease of bone. J Clin Invest (2005) 1.92
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut (2005) 1.91
Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol (2006) 1.89
Current developments in salivary diagnostics. Biomark Med (2010) 1.83
Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A (2001) 1.81
Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone (2007) 1.79
PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab (2010) 1.77
Requirement for both micron- and submicron scale structure for synergistic responses of osteoblasts to substrate surface energy and topography. Biomaterials (2007) 1.71
Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol (2011) 1.70
Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell (2014) 1.70
Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol (2013) 1.70
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging (2010) 1.69
PTH and PTHrP signaling in osteoblasts. Cell Signal (2009) 1.69
Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol (2006) 1.67
Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest (2000) 1.67
Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol (2011) 1.66
Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. Int J Exp Pathol (2000) 1.66
Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood (2010) 1.66
Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One (2013) 1.64
M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest (2005) 1.64
Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci U S A (1998) 1.63
Nitric oxide and bone. Immunology (2001) 1.60
Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum (2005) 1.58
Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep (2014) 1.57
Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res Ther (2012) 1.55
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res (2008) 1.54
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol (2002) 1.53
NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest (2009) 1.52
NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. Mol Cell Biol (2005) 1.52
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas (2010) 1.51
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest (1999) 1.50
Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med (2009) 1.50
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol (1991) 15.04
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell (1996) 9.68
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Oncogene jun encodes a sequence-specific trans-activator similar to AP-1. Nature (1988) 7.45
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell (1988) 6.75
floricaula: a homeotic gene required for flower development in antirrhinum majus. Cell (1990) 6.52
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Profound block in thymocyte development in mice lacking p56lck. Nature (1992) 5.48
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 5.27
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis (2013) 4.51
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol (1990) 4.27
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev (1998) 3.92
Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev (2000) 3.86
Neural activity relating to generation and representation of galvanic skin conductance responses: a functional magnetic resonance imaging study. J Neurosci (2000) 3.49
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A (2000) 3.37
The dynamics of alcohol and marijuana initiation: patterns and predictors of first use in adolescence. Am J Public Health (2000) 3.11
Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell (1993) 3.07
Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science (1991) 2.99
One-dimensional electrical contact to a two-dimensional material. Science (2013) 2.87
Solubilization and partial purification of tyrosine hydroxylase from bovine adrenal medulla. J Biol Chem (1971) 2.85
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Measurements of energetic particle radiation in transit to Mars on the Mars Science Laboratory. Science (2013) 2.83
Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol (2012) 2.83
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Domains in the SPT5 protein that modulate its transcriptional regulatory properties. Mol Cell Biol (2000) 2.74
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood (1997) 2.71
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys (1995) 2.58
A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J Biol Chem (2001) 2.58
Antitermination by bacteriophage lambda Q protein. Cold Spring Harb Symp Quant Biol (1998) 2.57